{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:45:38Z","timestamp":1793375138152,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jtct.2025.03.007","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T15:18:53Z","timestamp":1742224733000},"page":"407-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Nephrotoxicity in CAR-T Cell Therapy"],"prefix":"10.1016","volume":"31","author":[{"given":"Karol","family":"Sadowski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9754-8001","authenticated-orcid":false,"given":"Weronika","family":"Ploch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Downar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktoria","family":"Giza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0654-2129","authenticated-orcid":false,"given":"Dorota","family":"Szcze\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wioletta","family":"Olejarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6813-3331","authenticated-orcid":false,"given":"Wies\u0142aw W.","family":"J\u0119drzejczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Ma\u0142yszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3858-8180","authenticated-orcid":false,"given":"Grzegorz","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2025.03.007_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000511107","article-title":"Personalized Immuno-Oncology","volume":"30","author":"Jain","year":"2021","journal-title":"Med Princ Pract"},{"issue":"4","key":"10.1016\/j.jtct.2025.03.007_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041003","article-title":"Systematic review on CAR-T cell clinical trials up to 2022","volume":"15","author":"Wang","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.jtct.2025.03.007_bib0003","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124303","article-title":"CAR-T Cell Therapy","volume":"21","author":"Ahmad","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.007_bib0004","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtct.2025.03.007_bib0005","unstructured":"Administration USFaD. Approved Cellular and Gene Therapy Products. 2024. Available at: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products. Accessed November 28, 2024."},{"issue":"4","key":"10.1016\/j.jtct.2025.03.007_bib0006","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1016\/j.clml.2020.12.010","article-title":"Systematic review and meta-analysis of CD19-specific CAR-T cell therapy in relapsed\/refractory acute lymphoblastic leukemia in the pediatric and young adult population: safety and efficacy outcomes","volume":"21","author":"Aamir","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2025.03.007_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1178403","article-title":"A systematic review and meta-analysis of CD22 CAR T-cells alone or in combination with CD19 CAR T-cells","volume":"14","author":"Fergusson","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.007_bib0008","doi-asserted-by":"crossref","first-page":"569","DOI":"10.21037\/tcr-22-344","article-title":"Efficacy and safety of chimeric antigen receptor (CAR)-T cell therapy in the treatment of relapsed and refractory multiple myeloma: a systematic-review and meta-analysis of clinical trials","volume":"11","author":"Li","year":"2022","journal-title":"Transl Cancer Res"},{"issue":"1","key":"10.1016\/j.jtct.2025.03.007_bib0009","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"10.1016\/j.jtct.2025.03.007_bib0010","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor t cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"issue":"11","key":"10.1016\/j.jtct.2025.03.007_bib0024","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.clml.2022.07.007","article-title":"Impact of chronic kidney disease and acute kidney injury on safety and outcomes of CAR T-cell therapy in lymphoma patients","volume":"22","author":"Ahmed","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2025.03.007_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107072","article-title":"Chimeric antigen receptor T cell therapy and nephrotoxicity: From diagnosis to treatment strategies","volume":"89","author":"Zhou","year":"2020","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.007_bib0012","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute kidney injury after CAR-T cell therapy: low incidence and rapid recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.03.007_bib0013","article-title":"A prospective investigation of bispecific CD19\/22 CAR T cell therapy in patients with relapsed or refractory B cell non-Hodgkin lymphoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2025.03.007_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1252811","article-title":"Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT Transplant Complications and Lymphoma Working Party","volume":"14","author":"Penack","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.007_bib0019","doi-asserted-by":"crossref","first-page":"sfae027","DOI":"10.1093\/ckj\/sfae027","article-title":"Transient acute kidney injury after chimeric antigen receptor T-cell therapy in patients with hematological malignancies","volume":"17","author":"Le\u00f3n-Rom\u00e1n","year":"2024","journal-title":"Clin Kidney J"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.007_bib0022","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/j.ajkd.2020.08.017","article-title":"Acute kidney injury after the CAR-T therapy tisagenlecleucel","volume":"77","author":"Lee","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jtct.2025.03.007_bib0023","article-title":"Acute kidney injury following treatment with CD19-specific CAR T-cell therapy in children, adolescent and young adult patients with B-cell acute lymphoblastic leukemia","author":"Petgrave","year":"2023","journal-title":"Res Sq"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.007_bib0025","doi-asserted-by":"crossref","first-page":"686","DOI":"10.21037\/tp-20-323","article-title":"The advantage of chimeric antigen receptor T cell therapy in pediatric acute lymphoblastic leukemia with E2A-HLF fusion gene positivity: a case series","volume":"10","author":"Wu","year":"2021","journal-title":"Transl Pediatr"},{"issue":"4","key":"10.1016\/j.jtct.2025.03.007_bib0034","doi-asserted-by":"crossref","first-page":"c179","DOI":"10.1159\/000339789","article-title":"KDIGO clinical practice guidelines for acute kidney injury","volume":"120","author":"Khwaja","year":"2012","journal-title":"Nephron Clin Pract"},{"issue":"7","key":"10.1016\/j.jtct.2025.03.007_bib0020","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.mayocp.2022.05.018","article-title":"Incidence and risk factors for acute kidney injury after chimeric antigen receptor T-cell therapy","volume":"97","author":"Farooqui","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"24","key":"10.1016\/j.jtct.2025.03.007_bib0014","doi-asserted-by":"crossref","first-page":"11063","DOI":"10.1111\/jcmm.17029","article-title":"Predictive role of endothelial cell activation in cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukaemia","volume":"25","author":"Hong","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.007_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15031022","article-title":"Does cytokine-release syndrome induced by CAR T-Cell treatment have an impact on the pharmacokinetics of meropenem and piperacillin\/tazobactam in patients with hematological malignancies? Findings from an observational case-control study","volume":"15","author":"Liu","year":"2023","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.007_bib0016","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"Sidana","year":"2024","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.jtct.2025.03.007_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.09.009","article-title":"Outcomes of CD19-targeted chimeric antigen receptor T cell therapy for patients with reduced renal function including dialysis","volume":"28","author":"Wood","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.007_bib0021","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11596-021-2373-7","article-title":"Anti-BCMA CAR-T cell therapy in relapsed or refractory multiple myeloma patients with impaired renal function","volume":"41","author":"He","year":"2021","journal-title":"Curr Med Sci"},{"issue":"2","key":"10.1016\/j.jtct.2025.03.007_bib0026","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/ajt.16367","article-title":"CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder","volume":"21","author":"Krishnamoorthy","year":"2021","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.03.007_bib0027","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-022-00266-1","article-title":"Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis","volume":"11","author":"Hunter","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2025.03.007_bib0028","doi-asserted-by":"crossref","first-page":"9627","DOI":"10.3390\/curroncol30110697","article-title":"Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed\/Refractory Multiple Myeloma: Preliminary Efficacy and Safety","volume":"30","author":"Das","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtct.2025.03.007_bib0029","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5414\/CNCS111045","article-title":"Thrombotic microangiopathy following chimeric antigen receptor T-cell therapy","volume":"11","author":"Wu","year":"2023","journal-title":"Clin Nephrol Case Stud"},{"key":"10.1016\/j.jtct.2025.03.007_bib0030","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1288764","article-title":"Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment","volume":"13","author":"Marquard","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.03.007_bib0031","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s40364-023-00532-2","article-title":"First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma","volume":"11","author":"Korell","year":"2023","journal-title":"Biomark Res"},{"issue":"4","key":"10.1016\/j.jtct.2025.03.007_bib0032","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.xkme.2021.03.011","article-title":"Acute kidney injury following chimeric antigen receptor T-cell therapy for B-cell lymphoma in a kidney transplant recipient","volume":"3","author":"Melilli","year":"2021","journal-title":"Kidney Med"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.007_bib0033","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.xkme.2021.06.011","article-title":"Collapsing focal segmental glomerulosclerosis and acute kidney injury associated with chimeric antigen receptor T-cell (CAR-T) therapy: a case report","volume":"3","author":"Acharya","year":"2021","journal-title":"Kidney Med"},{"issue":"4","key":"10.1016\/j.jtct.2025.03.007_bib0048","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41409-022-01907-z","article-title":"CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review","volume":"58","author":"Portuguese","year":"2023","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.jtct.2025.03.007_bib0036","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1053\/j.ackd.2012.04.009","article-title":"The pathogenesis of acute kidney impairment in patients with multiple myeloma","volume":"19","author":"Batuman","year":"2012","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.007_bib0037","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/cncr.22904","article-title":"Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the Renal Insufficiency And Anticancer Medications (IRMA) Study","volume":"110","author":"Launay-Vacher","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2025.03.007_bib59","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s004670050760","article-title":"Interleukin-8 alters glomerular heparan sulfate glycosaminoglycan chain size and charge in rats","volume":"14","author":"Garin","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jtct.2025.03.007_bib0038","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2386187","article-title":"Immunotherapy with CAR-Modified T cells: toxicities and overcoming strategies","volume":"2018","author":"Sun","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.jtct.2025.03.007_bib0039","series-title":"Diagnostic Immunohistochemistry","first-page":"156","article-title":"Chapter 6 - Immunohistology of Non-Hodgkin Lymphoma","author":"Martin","year":"2011"},{"issue":"11","key":"10.1016\/j.jtct.2025.03.007_bib0040","first-page":"1072","article-title":"Prospective multicenter study on epidemiology of acute kidney injury in the ICU: a critical care nephrology Italian collaborative effort (NEFROINT)","volume":"77","author":"Piccinni","year":"2011","journal-title":"Minerva Anestesiol"},{"issue":"21","key":"10.1016\/j.jtct.2025.03.007_bib0041","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.007_bib0042","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1182\/bloodadvances.2019000525","article-title":"Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL","volume":"4","author":"Awasthi","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2025.03.007_bib0043","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.2215\/CJN.00830110","article-title":"Chronic kidney disease: an inherent risk factor for acute kidney injury?","volume":"5","author":"Singh","year":"2010","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1016\/j.jtct.2025.03.007_bib0044","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0002-9343(98)00409-4","article-title":"Infections following peripheral blood progenitor cell transplantation for lymphoproliferative malignancies: etiology and potential risk factors","volume":"106","author":"Ketterer","year":"1999","journal-title":"The American Journal of Medicine"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.007_bib0045","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/598622","article-title":"Vancomycin as part of initial empirical antibiotic therapy for febrile neutropenia in patients with cancer: pros and cons","volume":"29","author":"Feld","year":"1999","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.jtct.2025.03.007_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.idcr.2021.e01088","article-title":"Fusarium rhinosinusitis post chimeric antigen receptor T-cell therapy","volume":"24","author":"Chesdachai","year":"2021","journal-title":"IDCases"},{"key":"10.1016\/j.jtct.2025.03.007_bib0047","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1272798","article-title":"Case Report: Invasive fungal infection after anti-CD19 CAR-T cell therapy. Implication for antifungal prophylaxis","volume":"14","author":"Pennese","year":"2023","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10.1016\/j.jtct.2025.03.007_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055870","article-title":"Acute kidney injury in patients with newly diagnosed high-grade hematological malignancies: impact on remission and survival","volume":"8","author":"Canet","year":"2013","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jtct.2025.03.007_bib0049","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.19209","article-title":"Recommendations on acute kidney injury biomarkers from the Acute Disease Quality Initiative Consensus Conference: a consensus statement","volume":"3","author":"Ostermann","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.007_bib0050","article-title":"Acute kidney injury: biomarker-guided diagnosis and management","volume":"58","author":"Yoon","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"10.1016\/j.jtct.2025.03.007_bib0051","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ccc.2020.11.001","article-title":"Defining acute kidney injury","volume":"37","author":"Verma","year":"2021","journal-title":"Crit Care Clin"},{"key":"10.1016\/j.jtct.2025.03.007_bib0053","unstructured":"Administration USFaD. Fludarabine phosphate injection. prescribing information. 2022. Available at: https:\/\/www.fda.gov\/media\/163105\/download. Accessed November 28, 2024."},{"issue":"17","key":"10.1016\/j.jtct.2025.03.007_bib0054","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","article-title":"The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells","volume":"133","author":"Hirayama","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2025.03.007_bib0055","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat Med"},{"issue":"43","key":"10.1016\/j.jtct.2025.03.007_bib0056","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000022510","article-title":"Lymphodepletion chemotherapy revitalizes chimeric antigen receptor T cells contributing to regression of relapsed B-cell lymphoma: A case report","volume":"99","author":"Liang","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.007_bib0057","doi-asserted-by":"crossref","first-page":"e4749","DOI":"10.1371\/journal.pone.0004749","article-title":"Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma","volume":"4","author":"Wallen","year":"2009","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.jtct.2025.03.007_bib0058","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1182\/bloodadvances.2021006418","article-title":"Optimal fludarabine lymphodepletion is associated with improved outcomes after CAR T-cell therapy","volume":"6","author":"Fabrizio","year":"2022","journal-title":"Blood Advances"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725010954?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725010954?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T21:20:52Z","timestamp":1751577652000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725010954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":58,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S2666636725010954"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.03.007","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nephrotoxicity in CAR-T Cell Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}